Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.

Abstract

This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.

• Authors: Aeron C Hurt, David S Hui, Alan Hay, Frederick G Hayden
• Journal: Influenza and other respiratory viruses (Influenza Other Respir Viruses) Vol. 9 Issue 1 Pg. 20-31 (Jan 2015) ISSN: 1750-2659 [Electronic] England
• PMID: 25399715 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Chemical References

• Antiviral Agents
• Influenza Vaccines

Topics

• Antiviral Agents (therapeutic use)
• Communicable Diseases, Emerging
• Coronavirus Infections (drug therapy, epidemiology)
• Humans
• Immunocompromised Host
• Influenza Vaccines
• Influenza, Human (drug therapy, epidemiology, prevention & control, virology)
• Middle East Respiratory Syndrome Coronavirus
• Pandemics
• Respiratory Syncytial Virus Infections (drug therapy, epidemiology)
• Respiratory Tract Infections (drug therapy, epidemiology, prevention & control, virology)
• Virus Diseases (drug therapy, epidemiology, virology)